William A. Haseltine

Dr. William A. Haseltine

ACCESS Health International, New York, USA
orcid

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 1986 in Nature
Verified
Journal Article
Closed access
PDF file
JSJoseph Sodroski
Joseph Sodroski
WGWei Chun Goh
Wei Chun Goh
CRCraig Rosen
Craig Rosen
ADAndrew Dayton
Andrew Dayton
ETErnest Terwilliger
Ernest Terwilliger
William A. HaseltineWilliam A. Haseltine
William A. Haseltine

1 July 1991 in The FASEB Journal
Verified
Journal Article
Closed access
William A. HaseltineWilliam A. Haseltine
William A. Haseltine

18 January 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
LSLawrence Steinman
Lawrence Steinman
Roberto PatarcaRoberto Patarca
Roberto Patarca
William A. HaseltineWilliam A. Haseltine
William A. Haseltine
20 yr ago, a tribute appeared in this journal on the 70th anniversary of an animal model of disseminated encephalomyelitis, abbreviated EAE for experimental autoimmune encephalomyelitis. “Observations on Attempts to Produce Disseminated Encephalomyelitis in Monkeys” appeared in the Journal of Experimental Medicine on February 21, 1933. Rivers and colleagues were trying to understand what caused neurological reactions to viral infections like smallpox, vaccinia, and measles, and what triggered rare instances of encephalomyelitis to smallpox vaccines. The animal model known as EAE continues to display its remarkable utility. Recent research, since the 70th-anniversary tribute, helps explain how Epstein–Barr virus triggers multiple sclerosis via molecular mimicry to a protein known as GlialCAM. Proteins with multiple domains similar to GlialCAM, tenascin, neuregulin, contactin, and protease kinase C inhibitors are present in the poxvirus family. These observations take us a full circle back to Rivers’ first paper on EAE, 90 yr ago.

Verified
Journal Article
Open access
PDF file
William A. HaseltineWilliam A. Haseltine
William A. Haseltine
Roberto PatarcaRoberto Patarca
Roberto Patarca
Human genome projects in the 1990s identified about 20,000 protein-coding sequences. We are now in the RNA revolution, propelled by the realization that genes determine phenotype beyond the foundational central molecular biology dogma, stating that inherited linear pieces of DNA are transcribed to RNAs and translated into proteins. Crucially, over 95% of the genome, initially considered junk DNA between protein-coding genes, encodes essential, functionally diverse non-protein-coding RNAs, raising the gene count by at least one order of magnitude. Most inherited phenotype-determining changes in DNA are in regulatory areas that control RNA and regulatory sequences. RNAs can directly or indirectly determine phenotypes by regulating protein and RNA function, transferring information within and between organisms, and generating DNA. RNAs also exhibit high structural, functional, and biomolecular interaction plasticity and are modified via editing, methylation, glycosylation, and other mechanisms, which bestow them with diverse intra- and extracellular functions without altering the underlying DNA. RNA is, therefore, currently considered the primary determinant of cellular to populational functional diversity, disease-linked and biomolecular structural variations, and cell function regulation. As demonstrated by RNA-based coronavirus vaccines’ success, RNA technology is transforming medicine, agriculture, and industry, as did the advent of recombinant DNA technology in the 1980s.

Verified
Journal Article
Open access
PDF file
William A. HaseltineWilliam A. Haseltine
William A. Haseltine
Kim HazelKim Hazel
Kim Hazel
Roberto PatarcaRoberto Patarca
Roberto Patarca
First believed to be a simple intermediary between the information encoded in deoxyribonucleic acid and that functionally displayed in proteins, ribonucleic acid (RNA) is now known to have many functions through its abundance and intricate, ubiquitous, diverse, and dynamic structure. About 70–90% of the human genome is transcribed into protein-coding and noncoding RNAs as main determinants along with regulatory sequences of cellular to populational biological diversity. From the nucleotide sequence or primary structure, through Watson–Crick pairing self-folding or secondary structure, to compaction via longer distance Watson–Crick and non-Watson–Crick interactions or tertiary structure, and interactions with RNA or other biopolymers or quaternary structure, or with metabolites and biomolecules or quinary structure, RNA structure plays a critical role in RNA’s lifecycle from transcription to decay and many cellular processes. In contrast to the success of 3-dimensional protein structure prediction using AlphaFold, RNA tertiary and beyond structures prediction remains challenging. However, approaches involving machine learning and artificial intelligence, sequencing of RNA and its modifications, and structural analyses at the single-cell and intact tissue levels, among others, provide an optimistic outlook for the continued development and refinement of RNA-based applications. Here, we highlight those in gene therapy.

1 March 1997 in Scientific American
Verified
Journal Article
Closed access
William A. HaseltineWilliam A. Haseltine
William A. Haseltine